drugset / Trial / NCT00790296
Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue
Phase 2
Terminated
11 enrolled
UConn Health
Hollfelder foundation · collabSusan G. Komen Breast Cancer Foundation · collab
RandomizedCrossoverTriple-blindSupportive care
Summary
The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue. The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.
Timeline
- Start
- 2006-12
- Primary completion
- 2010-02
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PROTIRELIN | Protein / enzyme biologic | 0.5 mg | — |
| Subject | PROTIRELIN | Protein / enzyme biologic | 1.5 mg | — |